Top Markets
Coin of the day
BRIM Biotechnology, Inc. BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc.

6885
Rank in Stocks #22414
BRIM Biotechnology, Inc., a clinical-stage firm, specializes in developing... BRIM Biotechnology, Inc., a clinical-stage firm, specializes in developing innovative regenerative therapies to address both ophthalmic and degenerative joint conditions. Leading its pipeline is BRM 421, a topical ophthalmic solution designed to treat moderate-to-severe dry eye syndrome, which has successfully completed a Phase 2 clinical trial in the United States. The company's development efforts also encompass BRM 423, currently in Phase 1 clinical trials for severe corneal damage; BRM 424, also in Phase 1, targeting neurotrophic keratitis; and BRM 521, which aims to alleviate and repair tissue damage caused by osteoarthritis. Founded in 2013, BRIM Biotechnology is headquartered in Taipei, Taiwan.
Share Price
$0.66936954
Last synced: 2026-07-28
Market Cap
$89.04M
Change (1 day)
0.00%
Change (1 year)
-40.10%
Country
TW
Trade BRIM Biotechnology, Inc. (6885)

Category

P/B ratio for BRIM Biotechnology, Inc. (6885)
P/B ratio as of 2026 TTM: 0
According to BRIM Biotechnology, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for BRIM Biotechnology, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH